Reuters' saying Gazyva raised 3yr survival from 92% to "only" 94% makes it sound trifling, but it's a 25% reduction in 3yr risk of death. https://t.co/mPbXkGoDl9
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.